产品
编 号：F745491
分子式：C176H290N56O51S3
分子量：4102.73
分子式：C176H290N56O51S3
分子量：4102.73
产品类型
规格
价格
是否有货
结构图
CAS No: 1480724-61-5
产品详情
生物活性：
Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3). Vosoritide can be used in achondroplasia and dwarfism research.
体内研究：
Vosoritide (subcutaneous injection; 800 μg/kg; once daily; 20 d) treatment leads to improvement in skeletal parameters in Fgfr3 gain-of-function mutation mouse.Animal Model:Fgfr3Y367C/+ mice
Dosage:800 μg/kg
Administration:Subcutaneous injection; 800 μg/kg; once daily; 20 days
Result:Observed phenotypic changes including flattening of the skull, elongation of the snout, improvement of the anterior crossbite, larger paws and digits, and longer and straightened tibias and femurs.
体外研究：
Vosoritide (0.1 μM; 1 h) decreases NPR2 phosphorylation in chondrocytes.Vosoritide (0.1 μM; 6 d) improves chondrocyte differentiation and increases the proliferative growth plate area of cultured Fgfr3Y367C/+ femurs.Vosoritide (10 μM; overnight) reduces ERK1/2 activation in ACH growth-plate chondrocytes.
Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3). Vosoritide can be used in achondroplasia and dwarfism research.
体内研究：
Vosoritide (subcutaneous injection; 800 μg/kg; once daily; 20 d) treatment leads to improvement in skeletal parameters in Fgfr3 gain-of-function mutation mouse.Animal Model:Fgfr3Y367C/+ mice
Dosage:800 μg/kg
Administration:Subcutaneous injection; 800 μg/kg; once daily; 20 days
Result:Observed phenotypic changes including flattening of the skull, elongation of the snout, improvement of the anterior crossbite, larger paws and digits, and longer and straightened tibias and femurs.
体外研究：
Vosoritide (0.1 μM; 1 h) decreases NPR2 phosphorylation in chondrocytes.Vosoritide (0.1 μM; 6 d) improves chondrocyte differentiation and increases the proliferative growth plate area of cultured Fgfr3Y367C/+ femurs.Vosoritide (10 μM; overnight) reduces ERK1/2 activation in ACH growth-plate chondrocytes.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备